{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"48.9","upperLimit":"68.4","value":"59.4"},{"groupId":"OG001","lowerLimit":"58.4","upperLimit":"76.6","value":"68.5"},{"groupId":"OG002","lowerLimit":"43.6","upperLimit":"63.3","value":"54.0"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.2","upperLimit":"57.1","value":"47.5"},{"groupId":"OG001","lowerLimit":"41.7","upperLimit":"61.2","value":"51.9"},{"groupId":"OG002","lowerLimit":"29.8","upperLimit":"49.4","value":"39.7"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.1","upperLimit":"50.7","value":"41.0"},{"groupId":"OG001","lowerLimit":"32.4","upperLimit":"51.9","value":"42.3"},{"groupId":"OG002","lowerLimit":"18.0","upperLimit":"35.7","value":"26.5"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"109"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"OS rate at a landmark (12, 18, and 24 months) was defined as the Kaplan-Meier (K-M) estimated probability of participants who survived due to any cause at the landmark after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 1: Cemiplimab + Chemotherapy"},{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab","id":"OG001","title":"Part 1: Cemiplimab+AbbrevChemo+Ipilimumab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG002","title":"Part 1: Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Part 1 participants only","reportingStatus":"POSTED","timeFrame":"12 months, 18 months, 24 months","title":"Part 1: Estimated Survival Probability","type":"SECONDARY","unitOfMeasure":"Estimated percentage of participants"}